PEC

PEC Gears Up for NASDAQ Listing with $1 Billion Brand Partner Subsidy

Retrieved on: 
Friday, November 3, 2023

Pine Bluff, AR, Nov. 03, 2023 (GLOBE NEWSWIRE) -- In a landmark development that's set to redefine brand distribution, Partner E-Commerce (PEC) is gearing up for a remarkable debut on the NASDAQ stock exchange in 2026, fueled by a substantial $1 billion subsidy from brand partners.

Key Points: 
  • Pine Bluff, AR, Nov. 03, 2023 (GLOBE NEWSWIRE) -- In a landmark development that's set to redefine brand distribution, Partner E-Commerce (PEC) is gearing up for a remarkable debut on the NASDAQ stock exchange in 2026, fueled by a substantial $1 billion subsidy from brand partners.
  • The growth trajectory of PEC can be attributed to its visionary leadership and innovative solutions, redefining industry norms.
  • This accelerated progress towards NASDAQ listing is partly attributed to a significant $1 billion subsidy from brand partners.
  • This substantial contribution has propelled PEC's brand distribution efforts and contributed to exceptional sales for brand agency stores.

BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film

Retrieved on: 
Wednesday, October 4, 2023

NEW HAVEN, Conn., Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience, today provided an update on recent developments with its late-stage clinical programs as well as its patent portfolio for IGALMI™ (dexmedetomidine) sublingual film. These developments include meetings scheduled with the U.S. Food and Drug Administration (FDA) to discuss the TRANQUILITY and SERENITY III clinical programs and the receipt of two Notices of Allowance (NOAs) from the U.S. Patent and Trademark Office to extend method of use patent protection for sublingual dexmedetomidine.

Key Points: 
  • “The meetings with the FDA are critical components of our business strategy.
  • The briefing book submitted to FDA for the meeting includes results from 11 double-blind, placebo-controlled Phase 2 and 3 clinical trials evaluating the safety and efficacy of BXCL501.
  • The Company now has four U.S. patents claiming formulations of dexmedetomidine with exclusivity until 2039 currently listed in the Orange Book.
  • These patents further broaden the scope of intellectual property estate for IGALMI™ and for future potential indications.

Douglas & London, P.C. Announces Preliminary Approval by the Court of the Historic $13.6 Billion PFAS Settlements

Retrieved on: 
Wednesday, August 30, 2023

Douglas & London, P.C., is pleased to announce that the Court overseeing the AFFF MDL has granted preliminary approval to the proposed PFAS settlement, with 3M Company for up to $12.5B.

Key Points: 
  • Douglas & London, P.C., is pleased to announce that the Court overseeing the AFFF MDL has granted preliminary approval to the proposed PFAS settlement, with 3M Company for up to $12.5B.
  • The Court had previously granted preliminary approval for a $1.185B settlement with DuPont on August 22, 2023.
  • Notice to potential class members is now authorized to commence, and the settlements are well on their way towards final approval and implementation.
  • On August 22, 2023, the Court issued the preliminary approval order for the DuPont settlement, including approval of the form and contents of notice.

BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization

Retrieved on: 
Monday, August 14, 2023

ET today

Key Points: 
  • ET today
    NEW HAVEN, Conn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced its financial results for the second quarter ended June 30, 2023, and a strategic reprioritization to strengthen its focus and significantly reduce operating expenses.
  • Continuing to actively evaluate strategic options for OnkosXcel Therapeutics, including potential financing or strategic partnership, M&A, or sale.
  • Net Loss: BioXcel Therapeutics had a net loss of $53.5 million for the second quarter of 2023, compared to a net loss of $37.7 million for the same period in 2022.
  • ET to discuss its second quarter 2023 financial results and provide an update on recent operational highlights.

Gwangju Institute of Science and Technology Researchers Develop Highly Efficient Organometal Halide Perovskite Photoelectrodes for Water Splitting

Retrieved on: 
Thursday, August 10, 2023

GWANGJU, China, Aug. 10, 2023 /PRNewswire/ -- Currently, hydrogen is mainly produced by natural gas, which, unfortunately, also generates greenhouse gases such as carbon dioxide as by-products. Scientists argue that hydrogen produced this way, while economical, is not truly sustainable, and thus requires a more eco-friendly approach for its generation. Photoelectrochemical (PEC) water splitting based on solar energy is one such promising approach. However, its widespread application is limited by a lack of efficient photoanodes for catalyzing the rate-limiting oxygen evolution reaction (OER), an important reaction in PEC water splitting.

Key Points: 
  • Photoelectrochemical (PEC) water splitting based on solar energy is one such promising approach.
  • However, its widespread application is limited by a lack of efficient photoanodes for catalyzing the rate-limiting oxygen evolution reaction (OER), an important reaction in PEC water splitting.
  • Recently, organometal halide perovskites (OHPs) have emerged as a promising photoanode material on this front.
  • Further, it enhanced the light-soaking stability of the OHP cell, a crucial factor in real-world PEC water splitting.

Introducing Automated Parallel Peptide Purification with the PurePep® EasyClean Auto Kit, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, August 10, 2023

TORONTO , Aug. 10, 2023 /PRNewswire-PRWeb/ -- Join the featured speakers to learn about a breakthrough solution for automated parallel peptide purification, enabled by the PurePep® EasyClean (PEC) Auto Kit.

Key Points: 
  • Attendees will learn how smart chemistry can enable automated peptide purification in existing peptide synthesis systems.
  • Attendees will discover why the PurePep® EasyClean Auto Kit saves a significant amount of toxic solvents, promoting eco-conscious peptide manufacturing.
  • TORONTO , Aug. 10, 2023 /PRNewswire-PRWeb/ -- Join the featured speakers to learn about a breakthrough solution for automated parallel peptide purification, enabled by the PurePep® EasyClean (PEC) Auto Kit.
  • Don't miss this opportunity to learn first-hand how to revolutionize your peptide processes from start to finish with automated peptide purification in parallel.

Gyros Protein Technologies Introduces PurePep EasyClean Auto Kit for Automated Parallel Peptide Purification

Retrieved on: 
Thursday, July 27, 2023

Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents, and a pioneer in automated nanoliter-scale immunoassays, today announced the launch of its PurePep® EasyClean (PEC) Auto Kit for the automated parallel purification of peptides, accelerating downstream processes for research, development, and production of simple to complex peptide drugs and therapies.

Key Points: 
  • Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents, and a pioneer in automated nanoliter-scale immunoassays, today announced the launch of its PurePep® EasyClean (PEC) Auto Kit for the automated parallel purification of peptides, accelerating downstream processes for research, development, and production of simple to complex peptide drugs and therapies.
  • Based on Gyros Protein Technologies’ orthogonal PurePep EasyClean technology, the PEC Auto Kit utilizes a simple catch-and-release methodology for purification of chemically synthesized peptides.
  • The new Auto Kit allows users of the PurePep Chorus and Symphony® X synthesizer to perform peptide synthesis and purification on a single instrument, further increasing process efficiency.
  • Gyros Protein Technologies’ PEC Auto Kit requires up to 90% less hands-on time per peptide (6 minutes vs ~ 1 hour) and 90% less solvent consumption, facilitating parallel purification of 6 or more purified peptides in under 6 hours.

OSF HealthCare and Abundant Health Acquisition (aha!) announce partnership to streamline access to care

Retrieved on: 
Thursday, July 13, 2023

PEORIA, Ill., July 13, 2023 /PRNewswire/ -- OSF HealthCare and Abundant Health Acquisition (aha!)

Key Points: 
  • PEORIA, Ill., July 13, 2023 /PRNewswire/ -- OSF HealthCare and Abundant Health Acquisition (aha!)
  • This partnership extends the OSF HealthCare and aha!
  • OSF HealthCare has 15 hospitals – 10 acute care, five critical access - with 2,084 licensed beds throughout Illinois and Michigan.
  • OSF Innovation is a collaborative network of different disciplines that designs bold, strategic solutions to advance the future of health care.

Xpeedic Launches High-Speed Digital Signal Integrity, Power Integrity Suite at Design Automation Conference

Retrieved on: 
Monday, July 10, 2023

EDA 2023 Suite Includes 2.5/3DIC SI/PI Simulation for Advanced Packaging,3D EM Simulation, SI/PI and Multiphysics Analysis, High-Speed System Simulation

Key Points: 
  • EDA 2023 Suite Includes 2.5/3DIC SI/PI Simulation for Advanced Packaging,3D EM Simulation, SI/PI and Multiphysics Analysis, High-Speed System Simulation
    SAN FRANCISCO, July 10, 2023 (GLOBE NEWSWIRE) -- Xpeedic today launched its high-speed digital signal integrity and power integrity (SI/PI) suite with significant features and upgrades to advanced packaging and high-speed design domains as the 60th Design Automation Conference (DAC) opens at Moscone Center West here.
  • The Xpeedic EDA 2023 Suite includes 2.5D and 3D signal integrity and power integrity simulation for advanced packaging, along with three platforms to support 3D Electromagnetic (EM) simulation, multi-domain co-simulation and high-speed system simulation.
  • It allows rapid analysis of signal, power, and temperature to ensure compliance with defined specifications, facilitating design iterations.
  • The Xpeedic EDA 2023 Suite for high-speed digital SI/PI and multi-physics simulation platforms is shipping now.

BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related Agitation

Retrieved on: 
Thursday, June 29, 2023

Efficacy for this dose was supported by a number of secondary measures, including CGI-I and ACES.

Key Points: 
  • Efficacy for this dose was supported by a number of secondary measures, including CGI-I and ACES.
  • The primary endpoint was not met for the 40 mcg dose, with a 5.7 point reduction from baseline in PEC score.
  • “Today, there are approximately 100 million Alzheimer’s-related agitation episodes in the U.S. annually, and there are no episodic treatment options for these patients.
  • We believe that our data from TRANQUILITY II show that BXCL501 has the potential to treat acute episodes of agitation in patients with mild to moderate Alzheimer’s disease, if approved.